Kaposi's Sarcoma Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight

DelveInsight's "Kaposi's Sarcoma Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Kaposi's Sarcoma Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Kaposi's Sarcoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Kaposi's Sarcoma: An Overview
Kaposi's Sarcoma (KS) is a multicentric vascular tumor originating in the endothelial cells that line blood vessels and lymphatic vessels. KS is caused when tiny blood vessels develop below the surface of the skin, in the mouth, nose, eyes, or other parts of the body, such as the lymph nodes or lungs. Individuals with weak immune systems have a high risk of Kaposi's Sarcoma. The lesions of Kaposi's Sarcoma typically appear as painless purplish spots on the feet, legs, face, genital area, mouth, or lymph nodes. In severe Kaposi's Sarcoma, lesions may develop in the lungs and digestive tract.

Download a sample copy of the Market Report @ https://www.delveinsight.com/sample-request/kaposis-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key highlights of the Kaposi's Sarcoma Market Report
• As per Globocan (2020), the prevalence rate of Kaposi Sarcoma is 1.11 per 100,000 in the United States and its prevalence in the United Kingdom and Japan was found to be around 0.81/100,000 and 0.13/100,000, respectively.
• As per the study titled "Risk of Kaposi's Sarcoma after solid organ transplantation in the United States" conducted by Cahoon et al. (2018), KS incidence was 87% higher in men than women, over twofold greater in non-whites than whites, and two-fold higher in non‐US citizens than US citizens. KS incidence increased with age at transplant and decreased sharply with time since transplant, so that the highest incidence occurred within 1 year of transplant.
• KS was a rare disease before the AIDS epidemic in the early 1980s, when the reported incidence of classic KS ranged from 0.01 per 100,000 person-years for the UK and 0.2 per 100,000 person-years for the USA. Incidence of KS is currently reported to be ~200 fold higher in recipients of solid-organ transplants (i.e., in iatrogenic KS) than in the general population.

Kaposi's Sarcoma Epidemiology Segmentation in the 7MM
• Prevalent Cases
• Age-specific Cases
• Total Diagnosed Cases
• Gender-specific Cases
• Total Treated Cases

Kaposi's Sarcoma Treatment Market
The main forms of treatment for Kaposi's Sarcoma are Antiretroviral Therapy, Surgery, Photodynamic Therapy, Radiation Therapy, therapies using medications such as Chemotherapy, Topical medications, Targeted Therapy and Immunotherapy. Antiretroviral Therapy (ART) is the most important modes of treatment of Kaposi's Sarcoma. This therapy is usually used before any other treatment to reduce the symptoms and treat the tumor. ART can be given alone or can also be given in combination with the chemotherapy depending on the symptoms and severity of the disease. However, rarely, ART can also cause some infections and worsen the Kaposi's Sarcoma. This reaction is called immune reconstitution inflammatory syndrome (IRIS).

Explore more information about the treatment options @ https://www.delveinsight.com/report-store/kaposis-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Kaposi's Sarcoma Therapies
Therapies using the medications such as Chemotherapy, Topical Therapies and Immunotherapies are systemic therapies for destroying the cancer cells. Common ways to give systemic therapies include an intravenous (IV) tube placed into a vein using a needle or in a pill or capsule that is swallowed (orally). Targeted Therapies includes kinase inhibitors and immune-modulating drugs which blocks the growth and spread of cancer cells while limiting damage to healthy cells. Pomalidomide (Pomalyst) is approved to treat Kaposi's Sarcoma if antiretroviral treatment has not been successful and adults with any Kaposi's Sarcoma who are HIV-negative. Other drugs similar to Pomalidomide include lenalidomide (Revlimid) and thalidomide (Thalomid).

Kaposi's Sarcoma Market Insights
Treatment for single skin lesions may include Radiation Therapy and Surgery, however, treatment for skin lesions all over the body may include Chemotherapy as well. Treatment for Kaposi's Sarcoma that affects lymph nodes or the gastrointestinal tract usually includes chemotherapy with or without radiation therapy. Increasing number of patients undergoing organ transplant procedures is the leading cause for growth of the Kaposi's Sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. Lack of awareness about this cancer, irregular availability of chemotherapy and HAART, lack of radiotherapy services, and overall high cost of cancer treatment are major factors limiting growth of the Kaposi's Sarcoma treatment market.

Kaposi's Sarcoma Market Dynamics
The dynamics of Kaposi's Sarcoma market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies. Key players, such as Vasgene therapeutics and Bristol-Myers Squibb etc. are involved in developing drugs for Kaposi's Sarcoma.

Request a sample copy of the report @ https://www.delveinsight.com/sample-request/kaposis-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Kaposi's Sarcoma
3. Competitive Intelligence Analysis for Kaposi's Sarcoma
4. Kaposi's Sarcoma: Market Overview at a Glance
5. Kaposi's Sarcoma: Disease Background and Overview
6. Patient Journey
7. Kaposi's Sarcoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Kaposi's Sarcoma Unmet Needs
10. Key Endpoints of Kaposi's Sarcoma Treatment
11. Kaposi's Sarcoma Marketed Products
12. Kaposi's Sarcoma Emerging Therapies
13. Kaposi's Sarcoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Kaposi's Sarcoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

For queries & doubts, may speak to our Business Consultant @ https://www.delveinsight.com/report-store/kaposis-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.